HIV/AIDSNCT04027153
The Deliver Health Study
A study testing Fee based delivery in people with HIV/AIDS, run by University of Washington at 1 site in South Africa.
Trial summary
The investigators hypothesize that routing algorithm based ART delivery will be acceptable, efficient and improve health outcomes, specifically through meeting client needs, retaining HIV-positive persons in care, and achieving high ART resupply and viral suppression. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- HIV/AIDS
- What is being tested?
- Fee based delivery
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 162 participants
- Where
- 1 siteSouth Africa
- Study dates
- 7 Oct 2019to 6 Mar 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- HIV infected and clinically stable
- Eligible for ART according to national guidelines
- Willingness to reside in study community for duration of follow up
- Able and willing to sign the informed consent form
- Willing to pay for medication delivery
- Not known to be pregnant
Who cannot join
- No separate criteria
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Deliver Health Study: A Prospective, Interventional, Randomized Study of Fee for Home ART Delivery in KwaZulu-Natal, South Africa
The investigators hypothesize that routing algorithm based ART delivery will be acceptable, efficient and improve health outcomes, specifically through meeting client needs, retaining HIV-positive persons in care, and achieving high ART resupply and viral suppression. They also hypothesize that a fee for home delivery will improve retention and viral suppression among persons willing to pay a fee for ART delivery. The investigators propose to test ART delivery using routing science and fee for home delivery as strategies that could be scaled-up to sustain lifelong ART.
Read the detailed description
In KwaZulu-Natal (KZN), South Africa (SA), after an abrupt decline in the 1990s, life expectancy has dramatically rebounded - all driven by the tremendous progress in earlier initiation, once daily, and greater access to ART.23 Efficient ART delivery is key for increasing population coverage and maintaining suppression for life. However, in SA, of the 7.1 million HIV-positive persons, 56% are on ART, and only 45% are virally suppressed (the key indicator of treatment success). Men are less likely to be suppressed than women, due to barriers to care including clinic bottle-necks in ART provision. On a given day, up to 70% of a facility's prescription load is devoted to servicing repeat ART prescriptions. HIV-associated mortality continues to be high, particularly among hard to reach populations who do not regularly visit the clinic on a sufficiently frequent schedule to maintain uninterrupted ART and viral suppression. Over four years, a third of HIV-positive persons in SA are no longer retained in care. Clinically stable HIV-positive persons can safely and effectively receive ART resupply and monitoring in the community. In SA, efforts to deliver medications outside the clinic through the Centralised Chronic Medicines Dispensing and Distribution (CCMDD), led by Project Last Mile (PLM), are focused in urban areas. Data are needed on client preferences for modes of delivery in rural areas, as are innovative, high impact strategies to simplify ART delivery and facilitate life-long ART.
Decentralized ART resupply and monitoring supports successful differentiated service delivery (DSD). Differentiated service delivery (DSD) for HIV (i.e. a client-centered approach that simplifies and adapts services to reflect preferences and expectations of clients while reducing unnecessary burdens on the health system) has the potential to deliver HIV treatment, remove barriers to care, increase retention on ART, and ultimately prevent disability and death at a lower cost. DSD may also have the advantage of de-bulking the clinic allowing providers to focus on clients with medically complex cases. However, there is a fundamental need to match the demand for ART resupply and monitoring with the ART supply, accounting for client preferences for resupply from a local mobile van or at home for convenience and to avoid stigma at the clinic.
The goal of data-driven delivery algorithms is to match ART supply with demand. Amazon.com, the largest internet-based retailer globally, uses routing science extensively and is established in South Africa. Enormous expertise and successful implementation of efficient, low-cost, on-time delivery in diverse settings have been applied by Amazon to get goods to the right person at the right time. Amazon is building their capacity for delivery to rural areas in South Africa, the investigators target geographic location. Since minimal financial resources are available (NDoH pays ZAR 9.36 = USD 0.75 per refill) delivery optimization is essential. The classic computer science Travelling Salesman Problem is used to optimize vehicle routing for delivery through computer algorithms.
Specifically, the investigators propose to adapt vehicle routing algorithms to determine the placement of mobile vans for ART resupply and monitoring in the community. The study area is divided into community clusters of HIV-positive persons who require ART resupply and monitoring. Currently, the study coordinator decides on a weekly basis where the mobile van should be placed, which may not adequately account for multiple cofactors (distance, travel time, client availability). A routing algorithm would efficiently match ART demand with the supply and determine mobile van placement. Importantly, algorithms can use the enrollment GPS location of clients and do not require formal addresses. Routing science guided delivery has the potential to increase efficiency and coverage of ART resupply and monitoring, reduce logistic barriers for clients, and improve the cost efficiency to the health system.
The theoretical basis for proposing ART delivery to increase retention in care and viral suppression is implementation intention i.e. a strategy that automates action control such as planning to collect medication within a given window of availability or having the medication delivered. A fee for the service of home delivery of ART could also increase commitment to care through simplifying ART resupply, addressing logistic barriers (transportation costs, clinic hours), increasing perceived value, and strengthening implementation intentions. To address this separation between intention and action (unsuccessful intenders), cues and plans support engagement in health. Meta-analyses have demonstrated that implementation intentions have medium to large sized effects on behavioral outcomes. Paying a modest fee for home delivery has the potential to increase implementation intention through immediacy and the redundancy of further "conscious intent" (i.e. no additional planning required for clinic collections), simplifying the resupply process. Practically, a fee for home delivery could offset some of the costs of decentralized delivery, making it more appealing to government/investors.
Conceptual model for strengthening ART delivery: Concerns about decentralized ART delivery include how clients would access clinic care, the need for providers to monitor ART, implementation challenges, and concerns about disclosure with home ART delivery. To address these concerns, the investigators are using the evidence integration approach, adapted from Glasgow and colleagues in the investigators current Delivery Optimization for ART (DO ART) Study. The investigators are working with key stakeholders at the department of health, policy makers, clients, and advocates to review evidence and rationale behind decentralized ART delivery and monitoring and assess how to target strategies for scale-up.
Preliminary data: In a series of studies, which demonstrate the investigators capacity to conduct rigorous evaluation of community-based HIV testing and linkage strategies, and utilize study results including costs to contribute to policy, the investigators demonstrated that community-based HIV testing and counseling (HTC) results in >90% knowledge of serostatus and similarly high linkage rates for HIV-positive persons to HIV clinic, which was cost-effective. Results from the investigators work supported the World Health Organization HIV testing guidelines. However, drop-offs in HIV care resulted in only 60% of ART-eligible persons achieving viral suppression (the Linkages Study). Logistic barriers at the clinic such as long wait times, inconvenient hours, and multiple visits are barriers to sustained ART adherence. Preliminary data on spatial analyses: In the Linkages Study the investigators collected GPS data on the location of households and clinics and road map distances. These data demonstrate the investigators ability to collect and utilize geospatial data in statistical analyses.
Significance summary: the investigators hypothesize that routing algorithm based ART delivery will be acceptable, efficient and improve health outcomes, specifically through meeting client needs, retaining HIV-positive persons in care, and achieving high ART resupply and viral suppression. They also hypothesize that a fee for home delivery will improve retention and viral suppression among persons willing to pay a fee for ART delivery. The investigators propose to test ART delivery using routing science and fee for home delivery as strategies that could be scaled-up to sustain lifelong ART.
This proposal is highly innovative and creative in three ways. First, while simplified, decentralized client- centered ART delivery is essential for successful scale-up and lifelong adherence, current strategies do not use routing science methods and are not client-centered; they rely on existing businesses for pick-up points in urban areas. Working closely with the world's largest, successful internet retailer (Amazon.com), the investigators will adapt highly successful delivery algorithms methods to efficiently supply ART in rural settings outside of existing formal facilities utilizing client data on resupply needs, delivery preferences, and availability for pick-up. Second, they will leverage GPS guided delivery in areas without a formal address system, thus increasing overall coverage for decentralized ART delivery. Third, a small fee paid by the client could offset costs of home delivery in a system with an extremely small margin (ZAR 9.36 = USD 0.75 is paid by NDoH for each medication pick-up conducted by CCMDD in the private urban sector). Testing willingness to pay for services to simplify delivery is innovative as the strategy could increase funds for HIV care making home delivery cost neutral.
- Conditions
- HIV/AIDS
- Being tested
- Fee based delivery
- Medical subject headings
- Acquired Immunodeficiency Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fee based deliveryOther
Testing willingness to pay for services to simplify delivery is innovative as the strategy could increase funds for HIV care making home delivery cost neutral.
| Study group | Role | What they receive |
|---|---|---|
| Fee Arm | Experimental | Participants in this arm will pay a fee (based on an income sliding scale) to have their medication delivered to their location of choice. Receives: Other: Fee based delivery |
| Standard of Care Arm | Active comparator | Participants in this arm will pick up their medication refill at the local clinic Receives: Other: Fee based delivery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants in the Fee arm that paid for delivery
Paying a fee for home delivery of ART demonstrates feasibility and increases the proportion of HIV-positive persons achieving viral suppression, through simplifying resupply and monitoring, and is cost neutral.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jul 2019
- Study start7 Oct 2019
- Primary completion31 Dec 2020
- Study completion6 Mar 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for HIV/AIDSStudies of the same condition, open and under way.
- More trials run by University of WashingtonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- one to one on an individual level
- Masking
- None (open label)
- Enrolment
- 162 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Washington
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Responsible party
- Principal investigator, Ruanne Barnabas, University of Washington
- Investigators
- Ruanne V Barnaba, MBChB, DPhil, Principal investigator, University of Washington
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04027153
- Sponsor's protocol ID
- STUDY00005739
- Other IDs
- R21MH115770
- Status last verified
- Mar 2022
- First submitted
- 17 Jun 2019
- Last updated
- 4 Mar 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Tseng AS, Mugwanya KK, Szpiro AA, van Heerden A, Ntinga X, Schaafsma TT, Barnabas RV. Estimating the Effect of COVID-19 Pandemic Restrictions on Self-reported Antiretroviral Therapy Use and Late Refill Visits Among People Living With HIV in Rural South Africa. J Acquir Immune Defic Syndr. 2024 Aug 1;96(4):318-325. doi: 10.1097/QAI.0000000000003431.
PubMed 38916425Barnabas RV, Szpiro AA, Ntinga X, Mugambi ML, van Rooyen H, Bruce A, Joseph P, Ngubane T, Krows ML, Schaafsma TT, Zhao T, Tanser F, Baeten JM, Celum C, van Heerden A; Deliver Health Study Team. Fee for home delivery and monitoring of antiretroviral therapy for HIV infection compared with standard clinic-based services in South Africa: a randomised controlled trial. Lancet HIV. 2022 Dec;9(12):e848-e856. doi: 10.1016/S2352-3018(22)00254-5. Epub 2022 Nov 3.
PubMed 36335976
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Deliver Health Study: A Prospective, Interventional, Randomized Study of Fee for Home ART Delivery in KwaZulu-Natal, South Africa
- ClinicalTrials.gov ID
- NCT04027153
- Acronym / sponsor ID
- STUDY00005739
- Conditions
- HIV/AIDS
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 162 participants (actual)
- Lead sponsor
- University of WashingtonUniversity, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Study start
- 7 Oct 2019 (actual)
- Primary completion
- 31 Dec 2020 (actual)
- Study completion
- 6 Mar 2021 (actual)
- First posted
- 19 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators hypothesize that routing algorithm based ART delivery will be acceptable, efficient and improve health outcomes, specifically through meeting client needs, retaining HIV-positive persons in care, and achieving high ART resupply and viral suppression. They also hypothesize that a fee for home delivery will improve retention and viral suppression among persons willing to pay a fee for ART delivery. The investigators propose to test ART delivery using routing science and fee for home delivery as strategies that could be scaled-up to sustain lifelong ART.
Detailed description
In KwaZulu-Natal (KZN), South Africa (SA), after an abrupt decline in the 1990s, life expectancy has dramatically rebounded - all driven by the tremendous progress in earlier initiation, once daily, and greater access to ART.23 Efficient ART delivery is key for increasing population coverage and maintaining suppression for life. However, in SA, of the 7.1 million HIV-positive persons, 56% are on ART, and only 45% are virally suppressed (the key indicator of treatment success). Men are less likely to be suppressed than women, due to barriers to care including clinic bottle-necks in ART provision. On a given day, up to 70% of a facility's prescription load is devoted to servicing repeat ART prescriptions. HIV-associated mortality continues to be high, particularly among hard to reach populations who do not regularly visit the clinic on a sufficiently frequent schedule to maintain uninterrupted ART and viral suppression. Over four years, a third of HIV-positive persons in SA are no longer retained in care. Clinically stable HIV-positive persons can safely and effectively receive ART resupply and monitoring in the community. In SA, efforts to deliver medications outside the clinic through the Centralised Chronic Medicines Dispensing and Distribution (CCMDD), led by Project Last Mile (PLM), are focused in urban areas. Data are needed on client preferences for modes of delivery in rural areas, as are innovative, high impact strategies to simplify ART delivery and facilitate life-long ART.
Decentralized ART resupply and monitoring supports successful differentiated service delivery (DSD). Differentiated service delivery (DSD) for HIV (i.e. a client-centered approach that simplifies and adapts services to reflect preferences and expectations of clients while reducing unnecessary burdens on the health system) has the potential to deliver HIV treatment, remove barriers to care, increase retention on ART, and ultimately prevent disability and death at a lower cost. DSD may also have the advantage of de-bulking the clinic allowing providers to focus on clients with medically complex cases. However, there is a fundamental need to match the demand for ART resupply and monitoring with the ART supply, accounting for client preferences for resupply from a local mobile van or at home for convenience and to avoid stigma at the clinic.
The goal of data-driven delivery algorithms is to match ART supply with demand. Amazon.com, the largest internet-based retailer globally, uses routing science extensively and is established in South Africa. Enormous expertise and successful implementation of efficient, low-cost, on-time delivery in diverse settings have been applied by Amazon to get goods to the right person at the right time. Amazon is building their capacity for delivery to rural areas in South Africa, the investigators target geographic location. Since minimal financial resources are available (NDoH pays ZAR 9.36 = USD 0.75 per refill) delivery optimization is essential. The classic computer science Travelling Salesman Problem is used to optimize vehicle routing for delivery through computer algorithms.
Specifically, the investigators propose to adapt vehicle routing algorithms to determine the placement of mobile vans for ART resupply and monitoring in the community. The study area is divided into community clusters of HIV-positive persons who require ART resupply and monitoring. Currently, the study coordinator decides on a weekly basis where the mobile van should be placed, which may not adequately account for multiple cofactors (distance, travel time, client availability). A routing algorithm would efficiently match ART demand with the supply and determine mobile van placement. Importantly, algorithms can use the enrollment GPS location of clients and do not require formal addresses. Routing science guided delivery has the potential to increase efficiency and coverage of ART resupply and monitoring, reduce logistic barriers for clients, and improve the cost efficiency to the health system.
The theoretical basis for proposing ART delivery to increase retention in care and viral suppression is implementation intention i.e. a strategy that automates action control such as planning to collect medication within a given window of availability or having the medication delivered. A fee for the service of home delivery of ART could also increase commitment to care through simplifying ART resupply, addressing logistic barriers (transportation costs, clinic hours), increasing perceived value, and strengthening implementation intentions. To address this separation between intention and action (unsuccessful intenders), cues and plans support engagement in health. Meta-analyses have demonstrated that implementation intentions have medium to large sized effects on behavioral outcomes. Paying a modest fee for home delivery has the potential to increase implementation intention through immediacy and the redundancy of further "conscious intent" (i.e. no additional planning required for clinic collections), simplifying the resupply process. Practically, a fee for home delivery could offset some of the costs of decentralized delivery, making it more appealing to government/investors.
Conceptual model for strengthening ART delivery: Concerns about decentralized ART delivery include how clients would access clinic care, the need for providers to monitor ART, implementation challenges, and concerns about disclosure with home ART delivery. To address these concerns, the investigators are using the evidence integration approach, adapted from Glasgow and colleagues in the investigators current Delivery Optimization for ART (DO ART) Study. The investigators are working with key stakeholders at the department of health, policy makers, clients, and advocates to review evidence and rationale behind decentralized ART delivery and monitoring and assess how to target strategies for scale-up.
Preliminary data: In a series of studies, which demonstrate the investigators capacity to conduct rigorous evaluation of community-based HIV testing and linkage strategies, and utilize study results including costs to contribute to policy, the investigators demonstrated that community-based HIV testing and counseling (HTC) results in >90% knowledge of serostatus and similarly high linkage rates for HIV-positive persons to HIV clinic, which was cost-effective. Results from the investigators work supported the World Health Organization HIV testing guidelines. However, drop-offs in HIV care resulted in only 60% of ART-eligible persons achieving viral suppression (the Linkages Study). Logistic barriers at the clinic such as long wait times, inconvenient hours, and multiple visits are barriers to sustained ART adherence. Preliminary data on spatial analyses: In the Linkages Study the investigators collected GPS data on the location of households and clinics and road map distances. These data demonstrate the investigators ability to collect and utilize geospatial data in statistical analyses.
Significance summary: the investigators hypothesize that routing algorithm based ART delivery will be acceptable, efficient and improve health outcomes, specifically through meeting client needs, retaining HIV-positive persons in care, and achieving high ART resupply and viral suppression. They also hypothesize that a fee for home delivery will improve retention and viral suppression among persons willing to pay a fee for ART delivery. The investigators propose to test ART delivery using routing science and fee for home delivery as strategies that could be scaled-up to sustain lifelong ART.
This proposal is highly innovative and creative in three ways. First, while simplified, decentralized client- centered ART delivery is essential for successful scale-up and lifelong adherence, current strategies do not use routing science methods and are not client-centered; they rely on existing businesses for pick-up points in urban areas. Working closely with the world's largest, successful internet retailer (Amazon.com), the investigators will adapt highly successful delivery algorithms methods to efficiently supply ART in rural settings outside of existing formal facilities utilizing client data on resupply needs, delivery preferences, and availability for pick-up. Second, they will leverage GPS guided delivery in areas without a formal address system, thus increasing overall coverage for decentralized ART delivery. Third, a small fee paid by the client could offset costs of home delivery in a system with an extremely small margin (ZAR 9.36 = USD 0.75 is paid by NDoH for each medication pick-up conducted by CCMDD in the private urban sector). Testing willingness to pay for services to simplify delivery is innovative as the strategy could increase funds for HIV care making home delivery cost neutral.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- one to one on an individual level
| Arm | Type | Receives |
|---|---|---|
| Fee Arm | Experimental | Other: Fee based deliveryParticipants in this arm will pay a fee (based on an income sliding scale) to have their medication delivered to their location of choice. |
| Standard of Care Arm | Active comparator | Other: Fee based deliveryParticipants in this arm will pick up their medication refill at the local clinic |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- HIV infected and clinically stable
- Eligible for ART according to national guidelines
- Willingness to reside in study community for duration of follow up
- Able and willing to sign the informed consent form
- Willing to pay for medication delivery
Key exclusion criteria (1 listed)
- No separate criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fee based deliveryTesting willingness to pay for services to simplify delivery is innovative as the strategy could increase funds for HIV care making home delivery cost neutral. | Other | Fee Arm, Standard of Care Arm |
Primary outcome
Number of participants in the Fee arm that paid for delivery
Time frame: 6 months
Paying a fee for home delivery of ART demonstrates feasibility and increases the proportion of HIV-positive persons achieving viral suppression, through simplifying resupply and monitoring, and is cost neutral.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2022.
- Derived from this study: PubMed 38916425Tseng AS, Mugwanya KK, Szpiro AA, van Heerden A, Ntinga X, Schaafsma TT, Barnabas RV. Estimating the Effect of COVID-19 Pandemic Restrictions on Self-reported Antiretroviral Therapy Use and Late Refill Visits Among People Living With HIV in Rural South Africa. J Acquir Immune Defic Syndr. 2024 Aug 1;96(4):318-325. doi: 10.1097/QAI.0000000000003431.
- Derived from this study: PubMed 36335976Barnabas RV, Szpiro AA, Ntinga X, Mugambi ML, van Rooyen H, Bruce A, Joseph P, Ngubane T, Krows ML, Schaafsma TT, Zhao T, Tanser F, Baeten JM, Celum C, van Heerden A; Deliver Health Study Team. Fee for home delivery and monitoring of antiretroviral therapy for HIV infection compared with standard clinic-based services in South Africa: a randomised controlled trial. Lancet HIV. 2022 Dec;9(12):e848-e856. doi: 10.1016/S2352-3018(22)00254-5. Epub 2022 Nov 3.
- Individual participant dataSharing planned: No
Related trials for HIV/AIDS
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
RecruitingPhase 2
Multiple Interventions With Distinct Anti-reservoir Activities in People on Antiretroviral Treatment
HIV - Human Immunodeficiency Virus
RecruitingPhase 2
CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial
HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma
Recruiting
Improving Engagement in HIV and Cancer Care in Zimbabwe
Cancer, HIV
RecruitingObservational study
Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection
HIV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ruanne V Barnaba, MBChB, DPhil principal investigator
University of Washington
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fee based delivery in people with HIV/AIDS, run by University of Washington at 1 site in South Africa.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants in the Fee arm that paid for delivery (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04027153, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2022.